{"id":16377,"date":"2026-06-19T08:34:30","date_gmt":"2026-06-19T05:34:30","guid":{"rendered":"https:\/\/nesiller.com\/non-hodgkin-lenfoma-nhl-testleri-paneli\/"},"modified":"2026-10-26T14:32:11","modified_gmt":"2026-10-26T11:32:11","slug":"non-hodgkin-lymphoma-nhl-panel","status":"publish","type":"page","link":"https:\/\/nesiller.com\/en\/oncology\/focus-hematology-panels\/non-hodgkin-lymphoma-nhl-panel\/","title":{"rendered":"Non-Hodgkin Lymphoma (NHL) Panel"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
FOCUS Hematology Panels<\/a><\/div>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Non-Hodgkin Lymphoma (NHL) Panel<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Non-Hodgkin Lymphoma (NHL)<\/strong> is a group of blood cancers that develop from lymphocytes, a type of white blood cell involved in the immune system. The disease occurs when abnormal lymphocytes grow uncontrollably and accumulate in lymph nodes or other tissues. Its development is associated with various factors, including genetic changes that affect cell growth and survival. Specific chromosomal abnormalities, such as translocations involving the MYC, BCL2, and CCND1 genes, are associated with certain NHL subtypes and can help characterize the disease.<\/p>

Treatment for Non-Hodgkin Lymphoma depends on the specific subtype, disease stage, and the patient’s overall health. Treatment options may include chemotherapy, immunotherapy, targeted therapies, radiotherapy, and stem cell transplantation in selected cases. Genetic and chromosomal analyses can support disease classification, risk assessment, and clinical decision-making in treatment planning.<\/p>
Genetic Alterations<\/strong><\/td>Method<\/strong><\/td>Sample Type<\/strong><\/td><\/tr>
7p13.1 (p53) Deletion<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
t(8;14)(q24;q32)<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
t(11;14)(q13;q32)<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
t(14;18)(q32;q21)<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
Trisomy \/ Monosomy\u00a07<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
Trisomy \/ Monosomy 8<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

FOCUS Non-Hodgkin Lymphoma (NHL) Panel analyzes p53 (17p13.1) deletion, t(8;14), t(11;14) and t(14;18) translocations and numerical changes of chromosomes 7 and 8 by FISH in bone marrow or heparinized blood.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":16386,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-16377","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/comments?post=16377"}],"version-history":[{"count":28,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16377\/revisions"}],"predecessor-version":[{"id":22034,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16377\/revisions\/22034"}],"up":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16386"}],"wp:attachment":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/media?parent=16377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}